CDC’s independent valuation surged 23.6% during the June quarter to a mid-point of A$18.5 billion, translating to a A$9.2 billion valuation of Infratil’s 49.72% stake. This A$1.76 billion increase in Infratil’s ownership value represents a material gain over three months and reflects strong operational momentum at the data centre operator. The valuation range of A$17.5 billion to A$19.7 billion provides investors with a reasonable width of outcomes, capturing the key uncertainties around growth execution and macro rate assumptions.
The valuation jump was driven by three primary factors working in concert. Contracted capacity exceeded 1GW for the first time, including a significant 555MW contract announced in May alongside 14MW of new agreements in New Zealand. Leasable operating capacity climbed by 90MW to 550MW, while capacity under construction doubled to 810MW, signalling CDC’s build programme is accelerating materially. The company also extended its pipeline disclosure period from FY34 to FY40 and expanded total leasable pipeline capacity to 3.9GW, representing a gain of 1.9GW from the prior 2.6GW figure.
The pipeline expansion warrants closer examination because it reflects two distinct movements. The 550MW released to the disclosed pipeline was previously assumed to build between FY34 and FY40, while 1.3GW represents entirely new capacity not previously modelled in valuations. This additional 1.3GW is targeted for key Australian markets where customer demand signals remain robust, giving CDC substantial runway to capitalise on ongoing secular trends in hyperscale data centre capacity and computing requirements.
One accounting adjustment deserves attention from long-term holders. CDC’s reporting shifted from built capacity to leasable capacity metrics and extended the disclosure horizon from FY34 to FY40. While these changes improve transparency around available capacity for customers, the 1.9GW pipeline increase includes this reclassification alongside genuinely new capacity additions. Investors comparing growth rates across periods should account for this reporting change to avoid overstating organic pipeline growth.
The quarter was not without headwinds to operational gains. The independent valuation incorporated a 25 basis point increase in the long-term risk-free rate, which flowed through to higher long-term forward yield assumptions, elevated interest cost forecasts, and increased cost of equity estimates. This valuation pressure offset some of the positive operational and contracted cash flow movements, though clearly insufficient to derail the strong 23.6% quarterly appreciation.
With contracted capacity now representing a meaningful portion of CDC’s operating and under-construction assets, the focus for investors shifts to delivery execution. Key metrics to monitor include progress in converting the 1.3GW of newly disclosed pipeline into contracted capacity over coming years, timing of the accelerated build programme to support the contracted base through FY29, and whether macro interest rate assumptions stabilise or deteriorate. This price-sensitive announcement, flagged by the ASX as material, reflects significant movements in Infratil’s largest asset and underscores management confidence in CDC’s long-term growth.
View the full ASX announcement (PDF)
About Infratil Limited (ASX: IFT)
Infratil Limited is a New Zealand-based infrastructure investment company listed on the ASX and NZX. The company invests in and operates renewable energy assets, airports, diagnostic imaging services, and digital infrastructure businesses across New Zealand, Australia, the United States, Asia, the United Kingdom, and Europe. Its portfolio includes renewable energy generators, Wellington International Airport, healthcare imaging networks, and telecommunications infrastructure.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
